Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrrheum.2015.179 http://scihub22266oqcxt.onion/10.1038/nrrheum.2015.179 C5851441!5851441!27009539     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Rheumatol 2016 ; 12 (5): 259-68 Nephropedia Template TP {{tp|p=27009539|t=2016. Macrophage activation syndrome in the era of biologic therapy |pdf=|usr=}}{{27009539}} gab.com Text Macrophage activation syndrome in the era of biologic therapy JO: Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27009539 #FOAvip Macrophage activation syndrome (MAS) refers to acute overwhelming inflammation caused by a ?cytokine storm?. Although increasingly recognized as a life-threatening complication of various rheumatic diseases, clinically, MAS is strikingly similar to primary and secondary forms of haemophagocytic lymphohistiocytosis (HLH). Not surprisingly, many rheumatologists prefer the term secondary HLH rather than MAS to describe this condition, and efforts to change the nomenclature are in progress. The pathophysiology of MAS remains elusive, but observations in animal models, as well as data on the effects of new anticytokine therapies on rates and clinical presentations of MAS in patients with systemic juvenile idiopathic arthritis (sJIA), provide clues to the understanding of this perplexing clinical phenomenon. In this Review, we explore the latest available evidence and discuss potential diagnostic challenges in the era of increasing use of biologic therapies. Twit Text FOAVip Macrophage activation syndrome in the era of biologic therapy ????Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27009539 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27009539 #FOAvip English Wikipedia <ref>{{Cite pmid|27009539}}</ref> Macrophage activation syndrome in the era of biologic therapy #MMPMID27009539 Grom AA; Horne A; De Benedetti F Nat Rev Rheumatol 2016[May]; 12 (5): 259-68 PMID27009539show ga Macrophage activation syndrome (MAS) refers to acute overwhelming inflammation caused by a ?cytokine storm?. Although increasingly recognized as a life-threatening complication of various rheumatic diseases, clinically, MAS is strikingly similar to primary and secondary forms of haemophagocytic lymphohistiocytosis (HLH). Not surprisingly, many rheumatologists prefer the term secondary HLH rather than MAS to describe this condition, and efforts to change the nomenclature are in progress. The pathophysiology of MAS remains elusive, but observations in animal models, as well as data on the effects of new anticytokine therapies on rates and clinical presentations of MAS in patients with systemic juvenile idiopathic arthritis (sJIA), provide clues to the understanding of this perplexing clinical phenomenon. In this Review, we explore the latest available evidence and discuss potential diagnostic challenges in the era of increasing use of biologic therapies. äMacrophage activation syndrome in the era of biologic therapy (epmc).pdf DeepDyve Pubget Overpricing